CHINA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

CHINA DIABETES CARE DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The China Diabetes Care Drugs Market is expected to register a CAGR greater than 2% forecast period, 2022-2027.

According to WHO, 20% of persons with diabetes and diabetes-related disorders died in China in January 2020 COVID-19 fatalities. Diabetes affects about one out of every ten COVID-19 patients in China. Diabetes is linked to an increased risk of serious disease and death. The current study suggests that COVID-19 individuals with diabetes require focused early intervention. According to a Peking University (Beijing China) research, intensive care unit (ICU) patients had an approximately threefold higher prevalence of diabetes than non-ICU patients. Various studies on the prevalence of diabetes have diverse results. During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, which was much greater than those without diabetes. Various studies on the prevalence of diabetes have diverse results. During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, which was much greater than those without diabetes. Importantly, respondents who reported medication shortages had a 63% higher rate of COVID-19 infection.

Type 1 diabetes patients will account for 9.84% of China's overall diabetes population in 2021. Blood glucose swings among insulin users are common in China owing to lifestyle and eating habits, and self-monitoring of blood glucose fails to adequately reflect the blood glucose profile since it only shows the glucose concentration at a single time point. Thus, a trend in the demand for Diabetes Drugs in China has been noted. In the pharmaceutical sector, insulin has a substantial market share. Insulin is used by around 100 million individuals worldwide, including all Type 1 diabetes patients and 10% to 25% of Type 2 diabetic patients. Insulin production is exceedingly complex, with just a few insulin manufacturers on the market. As a result, there is tremendous competition among these companies, which are always seeking to meet patient requests by offering the highest-quality insulin.

Key Market TrendsOral-Anti Diabetes Drugs is Having the Highest Market Share in 2021

The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 2.5% during the forecast period, mainly due to the demand from the diabetes population, which was more than 131 million by the end of 2022.

An uninterrupted supply of insulin is extremely important for all type 1 diabetes patients, as well as certain type 2 diabetes and gestational diabetic patients. Novo Nordisk, the worldwide insulin leader, controls a 20-billion-yuan market for human insulin and its analogs in China. On the other hand, oral hypoglycemic medications dominated the diabetic pharmaceutical market, with acarbose and metformin accounting for the majority of sales income. Aside from insulin and oral hypoglycemic medications, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are another kind of diabetic therapy that is expected to account for 21% of the market by 2030.

Among Chinese people who were not taking diabetes medication, 1.06% (95% CI 0.87%, 1.28%), or 5.37 (95% CI 4.36, 6.38) million were eligible for therapy but did not receive it. According to the 2020 CDS guideline, 1.27% (1.01%, 1.58%) of Chinese adults, or 6.44 (5.29, 7.60) million people, were not taking diabetes medication. Furthermore, a 0.21% (0.10%, 0.45%) or 1.07 (0.46, 1.69) million rise in the number of Chinese individuals with diabetes requiring antidiabetic therapy was estimated.

The Chinese government prioritizes healthcare. Beijing released the "Healthy China 2030" program in 2016, to boost the standard diabetes control rate to more than 70% by 2030. Aside from that, digital healthcare solutions and novel equipment are projected to propel China's diabetes care industry to new heights. Through the china government’s encouragement, the usage of Drugs increased over the forecast period.

The rising prevalence of diabetes in china is boosting the country's diabetes drug market.

Diabetes is a chronic condition that arises when the pancreas fails to make any or enough insulin, or when the body fails to correctly utilize the insulin that is produced. Diabetes is classified into three types: type 1, type 2 (the most prevalent), and gestational diabetes. Many of the early signs and symptoms of diabetes are modest and easy to overlook. In China, over two-thirds of diabetes patients were unaware of their illness and did not seek treatment. Diabetes, if left untreated, can lead to major health consequences such as cardiovascular disease, chronic renal disease, and stroke.

Diabetes is becoming increasingly prevalent in China. The world's most populated country has the largest amount of diabetes of any country on the planet. This figure is expected to rise to 147 million by 2045. According to health experts, the key causes of this spike include urbanization, improving living standards, and an aging population. As a result, the diabetes care market in China is predicted to expand gradually in the coming years.

According to estimations, one out of every ten Chinese residents in the country has diabetes. Every year in the twenty-first century, millions of new cases of diabetes are diagnosed. An accurate diabetes figure in China, however, is difficult to quantify because many cases are thought to go unreported. China is thought to have surpassed India as the country with the world's largest diabetic population. Diabetes is most common in China's cities, where economic expansion is increasing, and traditional eating habits are deteriorating. According to Chinese health experts, the primary causes of this increase in diabetes cases include urbanization, rising living standards, and an aging population. More hospitals in China will construct National Metabolic Management Centers (MMC) as part of their development of a new model of diabetes care, according to a national metabolic disease clinical research center. According to the National Health Commission, China Statistics, MMCs in China have served over 200,000 patients in the previous two years.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.